Tag: Jideytro
-
GSK Plans First-Line Jideytro Filing After 94% Response Rate
GSK plans to seek first-line FDA approval for Jideytro after the ROS1 inhibitor achieved a 94% response rate in 94 TKI-naïve patients in the ARROS-1 study.
-
Can GSK Deliver Its £40 Billion Growth Ambition?
GlaxoSmithKline (GSK) will unveil its long-term growth strategy on July 28. As CEO Luke Miels leads his first major investor event, the focus will be on whether oncology expansion and HIV transformation can realistically support the company’s £40 billion revenue ambition by 2031.